In addition, a secondary analysis of phase III clinical study CTONG 0901 found that exon 4 or 7 mutation of TP53 were independent prognostic factors for shortened PFS and OS in patients with EGFR-mutant advanced NSCLC. The gene discussed is TP53; the disease is non-small cell lung carcinoma.